marked.bio

KRAS G12D inhibitor ยท small molecule

INCB161734

2 active trials, targeting KRAS G12D. Not approved for any biomarker on marked.bio yet.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
KRAS G12D 2 2 Phase 3

Sponsors

Industry sponsors leading active biomarker-selected trials of INCB161734.

  1. Incyte 2

Trials

2 of 2 trials shown

  1. A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

    Recruiting Phase 3 Incyte Started 2026Primary completion 2028-09 NCT07522073

    INCB161734

    Histologically or cytologically confirmed metastatic PDAC with a KRAS G12D mutation

    KRAS G12DSolid Tumors

  2. A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

    Recruiting Phase 1 Incyte Started 2024Primary completion 2027-01 NCT06179160

    INCB161734cetuximabretifanlimabGEMNabPmFOLFIRINOXFOLFOXFOLFIRIINCA33890

    Locally advanced or metastatic solid tumor with KRAS G12D mutation.

    KRAS G12DSolid Tumors